Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

NCT03540303 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

NCT06641024 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

NCT04833504 ·Status: COMPLETED

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

NCT03263208 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

NCT07043218 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

NCT06830031 ·Status: RECRUITING ·Phase: PHASE1

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

NCT04850560 ·Status: UNKNOWN ·Phase: PHASE1

CD19-targeting CAR T Cells for B Cell Lymphoma

NCT02547948 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

NCT04215016 ·Status: UNKNOWN ·Phase: PHASE1

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160 ·Status: UNKNOWN ·Phase: NA

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

NCT07344818 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors

NCT06720324 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

NCT06210243 ·Status: TERMINATED ·Phase: PHASE1

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07234045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

NCT03101709 ·Status: UNKNOWN ·Phase: PHASE1

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

NCT04781634 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

NCT04219319 ·Status: TERMINATED ·Phase: PHASE1

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT05651100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

NCT06756321 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

NCT05436223 ·Status: RECRUITING ·Phase: PHASE2

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

NCT03544021 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04648475 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

NCT07097207 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Dual Target CAR-T Cells in B-cell Lymphoma

NCT04723914 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2